Eli Lilly beats Q3 revenue forecasts, lifts full-year outlook
read at Endpoints ↗EarningsPositive
Eli Lilly reported third-quarter revenue of $24.4 billion, roughly $2 billion above analysts' expectations.
The outperformance underscores the company's strong position, driven in part by its GLP-1 drug portfolio.
Following the beat, Lilly raised its full-year revenue outlook for the third consecutive quarter, reinforcing confidence among investors.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lilly again far surpasses revenue expectations”
read at Endpoints ↗82 words · retrieved 44m ago
comments(0)
5-min edit window · permanent after that